Baird raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $50 from $44 and keeps an Outperform rating on the shares. The firm said they reported a solid beat over expectations driven by Livmarli, leading them to raise FY2024 guidance above the top end of the previous range.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM: